Related Experiment Videos
Pharmacological studies on taurohyodeoxycholic acid
A S Tripodi1, S Contos, R Germogli
1Institute of Pharmacology II, University of Pavia, Italy.
Arzneimittel-Forschung
|August 1, 1993
Summary
Taurohyodeoxycholic acid (THDCA) promotes bile flow and reduces gallstone formation. This study found THDCA safe, with no significant effects on the central nervous system or cardiovascular system.
Area of Science:
- Pharmacology
- Gastroenterology
- Hepatology
Background:
- Taurohyodeoxycholic acid (THDCA) is a bile acid proposed for its anticholelithogenic properties.
- Understanding its pharmacological profile is crucial for its clinical application.
Purpose of the Study:
- To evaluate the anticholelithogenic and choleretic effects of THDCA.
- To assess the general pharmacological actions of THDCA on the central nervous, cardiovascular, and gastrointestinal systems.
Main Methods:
- Pharmacological screening for CNS, cardiovascular, and gastrointestinal effects.
- Assessment of biliary flow and solids content after intraduodenal THDCA administration.
- Evaluation of gallstone and steatosis incidence in mice on a lithogenic diet treated with THDCA.
Main Results:
- THDCA demonstrated no significant activity on the central nervous system (CNS), including locomotor activity, body temperature, coordination, respiration, or anticonvulsant and anticholinergic effects.
- THDCA did not cause significant changes in blood pressure or ECG.
- Intraduodenal THDCA administration increased biliary flow and biliary solids content.
- THDCA treatment significantly reduced the incidence of gallstones and hepatic steatosis in mice fed a lithogenic diet.
Conclusions:
- THDCA exhibits significant choleretic activity and effectively reduces gallstone and steatosis incidence.
- THDCA possesses a favorable safety profile, with no notable adverse effects on the CNS, cardiovascular, or gastrointestinal systems.
- THDCA is a promising agent for managing cholesterol gallstones and related liver conditions.